38
Participants
Start Date
October 31, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2027
Speech-generating device
The device is an iPad loaded with a grid-based and speech-generating communication application - a suitable application for the participant is determined at the beginning of the trial. This device is used in all 12 therapy sessions and implemented by a qualified speech pathologist in a natural, play-based setting.
Control
Participants will continue their current model of care. This means that if participants are receiving speech therapy locally, they may continue to do so given that no speech-generating device is introduced or used during this time. Participants will check in with the researching clinician at least once a week via telehealth or phone call - the aim is to stay in contact with families and reduce loss to follow-up. The clinician will also monitor treatment integrity and document any differences that may be present during this phase.
RECRUITING
Murdoch Children's Research Institute, Melbourne
Lead Sponsor
Murdoch Childrens Research Institute
OTHER